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background: The discovery of kisspeptin as key central regulator of GnRH secretion has led to a new level of understanding of the neu-
roendocrine regulation of human reproduction. The related discovery of the kisspeptin-neurokinin B-dynorphin (KNDy) pathway in the last
decade has further strengthened our understanding of the modulation of GnRH secretion by endocrine, metabolic and environmental inputs.
In this review, we summarize current understanding of the physiological roles of these novel neuropeptides, and discuss the clinical relevance
of these discoveries and their potential translational applications.
methods: A systematic literature search was performed using PUBMED for all English language articles up to January 2014. In addition, the
reference lists of all relevant original research articles and reviewswere examined. This review focusesmainly on published human studies but also
draws on relevant animal data.
results: Kisspeptin is a principal regulatorof the secretionof gonadotrophins, and through this key role it is critical for theonsetof puberty, the
regulation of sex steroid-mediated feedback and the control of adult fertility. Although there is some sexual dimorphism, both neuroanatomically
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and functionally, these functions areapparent in bothmenandwomen.Kisspeptin acts upstreamofGnRHand, followingparacrine stimulatoryand
inhibitory inputs from neurokinin B and dynorphin (KNDy neuropeptides), signals directly to GnRH neurones to control pulsatile GnRH release.
When administered to humans in different isoforms, routes and doses, kisspeptin robustly stimulates LH secretion and LH pulse frequency.
Manipulation of the KNDy system is currently the focus of translational research with the possibility of future clinical application to regulate
LHpulsatility, increasing gonadal sex steroid secretion in reproductive disorders characterized by decreased LHpulsatility, including hypothalamic
amenorrhoea and hypogonadotropic hypogonadism. Conversely there may be scope to reduce the activity of the KNDy system to reduce LH
secretion where hypersecretion of LH adds to the phenotype, such as in polycystic ovary syndrome.
conclusions: Kisspeptin is a recently discovered neuromodulator that controlsGnRHsecretionmediating endocrine andmetabolic inputs
to the regulation of human reproduction. Manipulation of kisspeptin signalling has the potential for novel therapies in patients with pathologically
low or high LH pulsatility.
Key words: kisspeptin / kisspeptin-neurokinin B-dynorphin / GnRH / LH pulsatility
Introduction
Since its discovery, hypothalamic secretion of GnRH has been robustly
established as the key pathway that initiates and controls reproductive
function. Whilst the pivotal central role played by GnRH remains undis-
puted, a number of functional limitations of theGnRH neuronal network
have been identiﬁed. For example, in rats, GnRH neurones lack estrogen
receptor (ER)-alpha (Herbison and Theodosis, 1992), the principal ER,
thus suggesting the need for an intermediary signalling pathwaymediating
gonadal feedback.
It was only a decade ago that the discovery of the obligate role of kis-
speptin in human puberty revolutionized current understanding of the
neuroendocrine regulation of human reproduction (de Roux et al.,
2003; Seminara et al., 2003). Kisspeptin, a hypothalamic peptide
coded by the KiSS1 gene, is a novel neuromodulator that acts upstream
ofGnRH, and is sensitive to sex steroid feedback andmetabolic cues. Kis-
speptin is now recognized as a crucial regulator of the onset of puberty,
the regulation of sex hormone-mediated secretion of gonadotrophins,
and the control of fertility (Pinilla et al., 2012). The related discovery of
a reproductive role for neurokinin B has stimulated further interest in
the ﬁeld. The same functional neuronal network secretes kisspeptin
and neurokinin B—now called kisspeptin-neurokinin B-dynorphin
(KNDy) neurones as they also co-secrete dynorphin, a well-established
opioid inhibitor (Goodman et al., 2007). Exogenous kisspeptin has been
administered tohealthy volunteers and a limitednumberof patients,with
a view to restoring reproductive function in certain conditions.
In this review,wesummarize current understandingof thephysiologic-
al regulation of GnRH pulse frequency by kisspeptin, and appraise the
clinical relevance of the discoveries of kisspeptin and neurokinin B. The
focus will predominantly be on human ﬁndings, using animal data
where human studies are lacking but where there is direct translational
potential.
Methods
A systematic literature search was performed using PUBMED for all English
language articles published up to January 2014 using the terms ‘kisspeptin’
and ‘reproduction’. The search was performed without limitations by
species although subsequent priority was given to human studies, where
available. The initial search identiﬁed 390 manuscripts, which were used as
backgroundmaterial for the review. In addition, the reference lists of all rele-
vant original research articles and reviews were examined and selected if
judged to be relevant. Relevant abstracts from recent scientiﬁc meetings
were included in the review.
Discovery of the kisspeptin and
KNDy neuronal network
KISS1 gene, peptide and its receptor
KISS1, the geneencoding kisspeptins,was originally identiﬁed in 1996 as a
suppressor of metastasis in human malignant melanoma (Lee et al.,
1996). As it was discovered in Hershey (PA, USA), the gene was
named after the famous chocolate ‘Kisses’ produced in the town. The
SS in KiSS1 acknowledges that it is a ‘suppressor sequence’.
The KISS1 gene is localized to chromosome 1q32 and has four exons,
the ﬁrst two of which are not translated (West et al., 1998). The gene
encodes the precursor 145 amino acid peptide, which is cleaved to a
54 amino acid protein (West et al., 1998). To acknowledge itsmetastasis
inhibitory properties, the 54 amino acid transcript was named ‘metastin’
(Ohtaki et al., 2001). This can be further cleaved to 14, 13 and 10 amino
acid peptides. The 54 amino acid and the shorter peptides belong to the
RF amide group of peptides, sharing the C-terminal sequence of
Arg-Phe-NH2, and are now collectively referred to as kisspeptins
(Kotani et al., 2001).
In 2001, kisspeptin was identiﬁed as a ligand for the orphan G-protein
coupled receptor 54 (GPR54), which was ﬁrst described in the rat brain
and subsequently in human (then named AXOR12 and hOT7T175)
(Lee et al., 1999; Muir et al., 2001; Ohtaki et al., 2001), now termed
KISS1R (Gottsch et al., 2009). KISS1R maps to chromosome 19p13.3
and includes ﬁve exons, encoding a 398 amino acid protein with seven
hydrophobic trans-membrane domains (Muir et al., 2001). It has an
amino acid sequence close to that of the galanin receptor family (40%
identity), although it does not bind either galanin or galanin-like
peptide (Lee et al., 1999). Upon binding by kisspeptin, KISS1R activates
phospholipase C and recruits secondary intracellular messengers, inosi-
tol triphosphateanddiacylglycerol,which in turnmediate calciumrelease
and protein kinase C activation to mediate kisspeptin’s function (Muir
et al., 2001; Liu et al., 2008; Constantin et al., 2009). Activation of
Kiss1r results in a biphasic increase in intracellular calcium, with a rapid
increase followed by a more sustained second phase (Min et al., 2014).
Tomaintain this second phase and therefore sustain signalling, kisspeptin
receptor trafﬁcking involving internalization, recycling and recruitment
from an intracellular pool, is required (Min et al., 2014). Without
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receptor trafﬁcking, the kisspeptin receptor undergoes desensitization
following an initial acute phase (Min et al., 2014). Since the discovery of
kisspeptin-KISS1R signalling, many different terms have been used to
describe its components. The nomenclature used in this review for
kisspeptin and its receptor will be that recently recommended by
Gottsch et al. (2009).
Functional neuroanatomy of kisspeptin
signalling
GnRHneurones extend from thepreoptic area through to the infundibu-
lar nucleus (homologue to the arcuate nucleus in other species) of the
hypothalamus in humans, whereas in rodents GnRH neurones reside
predominantly in the preoptic area (Lehman et al., 1986; Schwanzel-
Fukuda and Pfaff, 1989; Clifton and Steiner, 2009) (Fig. 1). GnRH
axons project from these nuclei to the median eminence, where
GnRH is secreted into theportal circulation in acoordinatedandpulsatile
manner. Similarly, kisspeptin neurones are located in the rostral preoptic
area and the infundibular nucleus in the human hypothalamus (Rometo
et al., 2007; Hrabovszky et al., 2010). The anatomical distribution of kis-
speptin neurones and their appositions with other hypothalamic endo-
crine networks are described below. Areas of incongruity between
data from human studies and those carried out in other species are
also highlighted.
Kisspeptin neurone localization in humans
Initial studies of the neuroanatomical distribution of kisspeptin neurones
in the human brain carried out in autopsy samples from premenopausal
and post-menopausal women localized KISS1 expression to the infun-
dibular nucleus only (Rometo et al., 2007). A more recent study, using
both male and female autopsy samples, has conﬁrmed the localization
of the majority of kisspeptin cell bodies in the infundibular nucleus, but
Figure 1 Schematic diagram showing the neuroanatomy of the kisspeptin-GnRH pathway and the relationship between KNDy neurones and GnRH
neurones in humans and rodents. Kisspeptin signals directly to the GnRH neurones, which express kisspeptin receptor. The location of kisspeptin
neurone populations within the hypothalamus is species speciﬁc, residing within the anteroventral periventricular nucleus (AVPV) and the arcuate
nucleus in rodents, and within the preoptic area (POA) and the infundibular nucleus in humans. Kisspeptin neurones in the infundibular (humans)/
arcuate (rodents) nucleus co-express neurokinin B and dynorphin (KNDy neurones), which via neurokinin B receptor and kappa opioid peptide receptor
autosynaptically regulatepulsatile kisspeptin secretion,withneurokininBbeing stimulatoryanddynorphin inhibitory.Negative (red) andpositive (green) sex
steroid feedback ismediated via distinct kisspeptin populations in rodents, via theAVPVand the arcuate nucleus, respectively. In humansKNDyneurones in
the infundibular nucleus relaybothnegative (red) andpositive (green) feedback.The roleof thePOAkisspeptin population inmediating sex steroid feedback
in humans is incompletely explored.ME,median eminence;+, stimulatory;2, inhibitory; ERa, estrogen receptor alpha; PR, progesterone receptor; Kiss1/
KiSS1, kisspeptin; NKB, neurokinin B; Dyn, dynorphin.
Kisspeptin pathway in human reproduction 3









identiﬁed a second dense population of kisspeptin cells in the rostral pre-
optic area (Hrabovszky et al., 2010).
Whilst kisspeptin neurones are located in the infundibular/arcuate
nucleus across all species, including humans, the rostral population is
species speciﬁc (Clarkson and Herbison, 2006; Pompolo et al., 2006;
Ramaswamy et al., 2008; Clarkson et al., 2009; Hrabovszky et al.,
2010). In rodents, the rostral population is located in the anteroventral
periventricular nucleus (AVPV) and the periventricular nucleus (PeN),
the continuum of this region known as the rostral periventricular
region of the third ventricle (RP3V) (Clarkson and Herbison, 2006;
Clarkson et al., 2009) (Fig. 1). In contrast, humans and ruminants lack
this well-deﬁned RP3V population and have more scattered kisspeptin
cell bodies within the preoptic region (Pompolo et al., 2006; Oakley
et al., 2009; Hrabovszky et al., 2010). Unlike in humans and ruminants,
Kiss1 mRNA was not detectable in the preoptic area in the adult
rhesus monkey (Ramaswamy et al., 2008).
Kisspeptin axons formdensepericapillaryplexuses in thehuman infun-
dibular stalk, the site of neurosecretion of GnRH (Hrabovszky et al.,
2010). Axo-somatic, axo-dendritic and axo-axonal contacts between
kisspeptin and GnRH axons were also demonstrated in the infundibular
stalk, in keeping with data from rodents, sheep andmonkeys, where kis-
speptin and GnRH neuronal networks are in close proximity (Clarkson
and Herbison, 2006; Ramaswamy et al., 2008; Smith et al., 2008a; Hra-
bovszky et al., 2010; Uenoyama et al., 2011). GnRH neurones express
Kiss1r mRNA (Irwig et al., 2004; Han et al., 2005; Messager et al.,
2005). These ﬁndings indicate direct involvement of kisspeptin in the
neurosecretion of GnRH. However, in humans as well as other species
studied to date, not all GnRH neurones receive kisspeptin neurone
contacts and the incidence of these contacts seems low (Clarkson
and Herbison, 2006; Ramaswamy et al., 2008; Smith et al., 2008a;
Hrabovszky et al., 2010), suggesting a subtle regulation of GnRH secre-
tion by kisspeptin and other neuropeptides.
Kisspeptin neurone populations co-express other neuropeptides
There is considerable overlap in thedistribution of kisspeptin, neurokinin
B and dynorphin in the hypothalamus, with frequent colocalization.
Mapping of kisspeptin and neurokinin B neurones was similar in the
infundibular nucleus of post-menopausal women, prompting the identi-
ﬁcation of a subpopulation of kisspeptin neurones which express neuro-
kinin B and dynorphin in the human infundibular nucleus (Rometo et al.,
2007;Hrabovszky et al., 2010). This unique region expressing kisspeptin,
neurokinin B and dynorphin is conserved across species and resides in
the hypothalamic arcuate nucleus in sheep and rodents (Burke et al.,
2006; Goodman et al., 2007; Navarro et al., 2009). Neurokinin B and
dynorphin are, however, absent from the kisspeptin population in the
preoptic area/RP3V. These infundibular (human)E/arcuate (rodent
and ruminant) nucleus neurones which co-express all three neuropep-
tides are referred to as KNDy neurones (Cheng et al., 2010) (Fig. 1).
KNDy neurones in rats and sheep also co-localize with the glutamate
transporter-2, and glutamate has been implicated in mediating estrogen
positive feedback resulting in the pre-ovulatory GnRH surge. Whether
KNDy cells express glutamate receptors remains to be determined
(Pompolo et al., 2003; Cioﬁ et al., 2006). Kisspeptin neurones in the pre-
optic area/RP3V are not KNDy neurones, but in the mouse AVPV they
co-express tyrosine hydroxylase (the key regulatory step in dopamine
synthesis) (Oakley et al., 2009). This differential expression of neuropep-
tides reﬂects complex signalling within the hypothalamus and distinct
functions of the two kisspeptin populations (Ojeda et al., 2010; Tello
et al., 2010).
Kisspeptin neurone populations differ in physiological function
KNDy neurones of the infundibular/arcuate nucleus inﬂuence the activ-
ity of GnRH by acting on both GnRH cell bodies and neurosecretory
terminals (Krajewski et al., 2005; Cioﬁ et al., 2006; Ramaswamy et al.,
2008) (Fig. 1). KNDy neurones make direct contact with GnRH cell
bodies and dendrites in humans and project to the median eminence
in rodents, sheep and monkeys (Krajewski et al., 2005; Cioﬁ et al.,
2006; Clarkson and Herbison, 2006; Ramaswamy et al., 2008; Dahl
et al., 2009). KNDy cells act synergistically to produce coordinated
and pulsatile GnRH secretion by controlling the neuroactivity of other
KNDy cells, as inferred from a reciprocally interconnected KNDy cell
network within the arcuate nucleus in the sheep and rat (Foradori
et al., 2002; Burke et al., 2006; Lehman et al., 2010). This is supported
by the expression of neurokinin B receptors and the kappa opioid
peptide receptor (the receptor for dynorphin) within the KNDy cells,
but not the kisspeptin receptor, which predominantly co-localizes with
GnRH neurones (Krajewski et al., 2005; Navarro et al., 2009; Herbison
et al., 2010) (Fig. 1). This implies that the stimulatory role of neurokinin B
and the inhibitory action of dynorphin autosynaptically coordinate the
pulsatile release of kisspeptin, which in turn drives the pulsatile secretion
of GnRH and LH (Navarro et al., 2009).
Kisspeptin-mediated GnRH stimulation is sex steroid dependent. Es-
trogen and progesterone modulate kisspeptin activity at both the AVPV
nucleus and the arcuate/infundibular nucleus through sex steroid recep-
tors (Cioﬁ et al., 1994; Goubillon et al., 2000; Foradori et al., 2002; Smith
et al., 2005; Franceschini et al., 2006) (Fig. 1). It is becoming clear that not
only do kisspeptin neurones mediate both negative and positive sex
steroid feedback, but also that distinct subgroups, which are species spe-
ciﬁc, are involved in these two critical regulatory functions, described
more fully below (sections: Kisspeptin mediates negative sex steroid
feedback andKisspeptinmayalsomediate estrogenic positive feedback).
In rodents, the AVPV and the arcuate nucleus respond to positive and
negative sex steroid feedback, respectively (Smith et al., 2005, 2006b,
Herbison, 2008), whereas in humans, the infundibular nucleus alone
relays sex steroid signalling (Rometo et al., 2007; Oakley et al., 2009)
(Fig. 1). Thus while there is less marked anatomical differentiation
of the two feedback pathways in humans, it remains possible
(and perhaps likely) that the two functions are mediated by different
neurones.
Kisspeptin neurones show sexual dimorphism
There is evidence for sexual dimorphism in kisspeptin pathways in the
human, probably reﬂecting these functional differences discussed
above. Female hypothalami have signiﬁcantly more kisspeptin ﬁbres in
the infundibular nucleus and ventral periventricular zone than are seen
in men (Hrabovszky et al., 2010). There is also a striking sex difference
in the number and expression of kisspeptin cell bodies, which are
observed in the rostral periventricular zone of the female only
(Hrabovszky et al., 2010). Likewise only a few kisspeptin cell bodies
are present in the infundibular nucleus in males in contrast to the abun-
dant kisspeptin cell bodies in females (Hrabovszky et al., 2010). Similarly,
sex differences have been reported in the arcuate nucleus of the sheep
(Cheng et al., 2010). Pre-ovulatory positive sex steroid feedback is
unique to the female, and the adult female mouse and rat hypothalamus
4 Skorupskaite et al.









contain 10-foldmore kisspeptin neurones thanmales in theRP3V region,
whereas the arcuate nucleus responsible for negative sex steroid feed-
back does not display such dimorphism (Clarkson and Herbison, 2006;
Kauffman et al., 2007).
Kisspeptin and the regulation
of GnRH secretion
Kisspeptin is a potent stimulator of the hypothalamic-pituitary-gonadal
(HPG) axis in both animalmodels and humans. Kisspeptin signals directly
to the GnRH neurones through the action on the kisspeptin receptor to
release GnRH into the portal circulation, which in turn stimulates the se-
cretion of LH and FSH from the gonadotrophs of the anterior pituitary.
Evidence for this comes from multiple sources. Since GnRH cannot be
measured in the peripheral circulation, LH pulse frequency remains a
widely used and a well validated surrogate of hypophyseal GnRH pulsa-
tility as each GnRH pulse is associated with an LH pulse (Clarke and
Cummins, 1985).
Kisspeptin stimulates gonadotrophin release
in humans
Kisspeptin stimulates the secretion of both LH and FSH in the human,
although the effect on the former is much more marked (George and
Seminara, 2012). Kisspeptin-54 was ﬁrst administered in healthy
men by intravenous infusion (4 pmol/kg/min (0.023 mg/kg/min) for
90 min) and resulted in a robust and dose-dependent increase (from
0.25 pmol/kg/min (0.001 mg/kg/min) to 12 pmol/kg/min (0.07 mg/
kg/min)) in LH, and less marked rises in FSH and testosterone (Dhillo
et al., 2005). Kisspeptin-54 clearance showed ﬁrst-order kinetics with
a half-life of 27.6+1.1 min (Dhillo et al., 2005), which compares with
about 4 min for kisspeptin-10 (Jayasena et al., 2011). The potency of kis-
speptin to stimulate the secretion of gonadotrophins and its preferential
effect on the releaseof LHhas been consistently observedwhenkisspep-
tin is administeredby different routes (intravenous or subcutaneous) and
types of exposure (single boluses or continuous infusion), in different iso-
forms (kisspeptin-54andkisspeptin-10), tomenorwomenor indifferent
disease models (Dhillo et al., 2005, 2007; Jayasena et al., 2009, 2010,
2011, 2013a, b; Chan et al., 2011, 2012; George et al., 2011, 2012,
2013; George and Seminara 2012; Abbara et al., 2013; Young et al.,
2013). Figures 2 and 3 summarize knowledge of the stimulatory effect
of exogenous kisspeptin on the secretion of LH in humans to date.
While kisspeptin stimulates LH release 2- to 3-fold in most circum-
stances, the stimulatory effect on FSH is much smaller and is less consist-
ent (Dhillo et al., 2005, 2007; George et al., 2011, 2012; Jayasena et al.,
2011; Chan et al., 2012). Amore potent effect of kisspeptin on LH secre-
tion than FSH in humans is concordant with studies in rodents (Thomp-
son et al., 2004; Navarro et al., 2005a).
Kisspeptin operates upstream of GnRH
neurones and coordinates GnRH and LH
pulsatility
Kisspeptin acts directly on GnRH neurones
Evidence that kisspeptin exerts its stimulatory function on gonadotroph-
in secretion through a direct action on the hypothalamic GnRH system is
provided by ﬁndings from animal studies, consistent with the anatomical
studies described above. Kisspeptin causes depolarization of and
increases in ﬁring rate of GnRH neurones in vitro (Han et al., 2005;
Zhang et al., 2008); kisspeptin stimulates the secretion of GnRH in hypo-
thalamic explants (Thompson et al., 2004; Tovar et al., 2006); c-Fos
immunoreactivity (a marker of neuronal activity) (Matsui et al., 2004;
Han et al., 2005) and the expression of GnRH mRNA is up-regulated
within the cell bodies of GnRH neurones following the kisspeptin expos-
ure (Novaira et al., 2009;Oakley et al., 2009). In sheep, intracerebroven-
tricular infusion of kisspeptin caused a dramatic increase in the
cerebrospinal ﬂuid GnRH content and simultaneously in serum LH and
FSH (Messager et al., 2005).
Some studies suggest that kisspeptin directly stimulates pituitary gona-
dotrophs to release LH and FSH, based on the expression of Kiss1 and
Kiss1r genes in gonadotrophs, the secretion of gonadotrophins from pi-
tuitary explants treated with kisspeptin (Kotani et al., 2001; Navarro
et al., 2005b, Gutierrez-Pascual et al., 2007; Richard et al., 2008) and
the detection of kisspeptin (although in low levels) in the hypophyseal
portal circulation in the sheep (Smith et al., 2008b). The ability of kisspep-
tin to induce gonadotrophin release from the pituitary fragments might
be explained by the pharmacological concentrations of kisspeptin used
(Navarro et al., 2005a, Gutierrez-Pascual et al., 2007).Whilst kisspeptin
may have a direct stimulatory action on gonadotrophs, indirect stimula-
tion through enhancing GnRH secretion appears to be the principal
physiologic pathway for the stimulation of gonadotrophin secretion
(Gottsch et al., 2004; Irwig et al., 2004; Smith et al., 2008b).
The physiological role of kisspeptin in the regulation of GnRH secre-
tion was further demonstrated by studies using a kisspeptin antagonist
(Millar et al., 2010). Kisspeptin-induced GnRH neurone ﬁring was abol-
ished by the kisspeptin antagonist (Irwig et al., 2004; Liu et al., 2008;
Roseweir et al., 2009). Kisspeptin is needed for the pulsatile release of
GnRH, as when injected into the median eminence of pubertal rhesus
monkeys, kisspeptin antagonist suppressed both mean GnRH and
GnRHpulses (Roseweir et al., 2009). Kisspeptinmodulates the secretion
of GnRH at the arcuate nucleus, the site of the GnRH pulse generator:
kisspeptin antagonist reduced LH pulse frequency when administered
to the arcuate nucleus but not when administered to the preoptic area
in the rat (Li et al., 2009).
That the effect of kisspeptin on LH releasewas prevented by pretreat-
mentwithGnRH antagonist further points to the action of kisspeptin up-
stream of GnRH (Gottsch et al., 2004; Shahab et al., 2005). Although
there are no studies in humans administering GnRH antagonist followed
by kisspeptin, the direct action of kisspeptin on GnRH neurones is in-
ferred from consistent ﬁndings in rodents and nonhuman primates.
Humans with ‘inactivating’ mutations in kisspeptin and/or its receptor
show hypogonadotropic hypogonadism and delayed puberty (de Roux
et al., 2003; Seminara et al., 2003),whist thosewith ‘activating’mutations
undergo precocious puberty (Teles et al., 2008; Silveira et al., 2010), sug-
gesting that kisspeptin modulates GnRH pulsatility.
Kisspeptin increases LH pulsatility in humans
As GnRH secretion is pulsatile, the effect of kisspeptin on the character-
istics of that pulsatility (as reﬂected in LH pulses) has been investigated.
Intravenous infusion of kisspeptin-10 (1.5 mg/kg/h (1.1 nmol/kg/h)
for 9 h) in healthymen (George et al., 2011) and kisspeptin-54 (subcuta-
neous bolus 0.3 nmol/kg (1.76 mg/kg) and 0.6 nmol/kg (3.5 mg/kg)) in
healthywomen (Jayasena et al., 2013c) increasedLHpulse frequencyand
amplitude. The ability of kisspeptin to enhance LH pulsatility has also
Kisspeptin pathway in human reproduction 5









been demonstrated in human reproductive disorders, including in hypo-
thalamic amenorrhoea (Jayasena et al., 2013a), in hypogonadal menwith
type2diabetes (George et al., 2013) and in neurokininB signalling defects
(Young et al., 2013), described more fully below. Kisspeptin not only
drives the pulsatile secretion of GnRH, but also appears to reset the
hypothalamic clock of GnRH pulsatility in men. Acute injection of
kisspeptin-10 delayed the next endogenous LH pulse by the interval
that would be observed between the two consecutive endogenous LH
pulses (Chan et al., 2011).However, the samekisspeptin dosingprotocol
did not support the ability of kisspeptin to reset the GnRH pulse gener-
ator in women across the different phases of the menstrual cycle (Chan
et al., 2012). The authors suggest that the GnRH pulse generator in men
operates differently towomen and that it is the changes in the sex steroid
milieu across themenstrual cycle inwomen thatmight be responsible for
this discrepancy (Chan et al., 2012). The marked sexual dimorphism in
the anatomy of the kisspeptin system described above may underlie
this intriguing observation and even determine the frequency of GnRH
secretion in women across the normal menstrual cycle. This variability
in the frequencyofGnRHpulsatility is central to thedifferential regulation
of LH and FSH (McNeilly et al., 2003) and thus ovarian follicle develop-
ment, the correct selection of a single dominant follicle for ovulation,
and the luteal phase with limited follicle development.
Men and women show sexual dimorphism
in their response to kisspeptin
Men andwomen display sexual dimorphism in their response to exogen-
ous kisspeptin (Fig. 2). Whilst kisspeptin potently stimulates the release
of LH in men, the effect of kisspeptin is more variable in women and
depends on the phase of the menstrual cycle. It has been proposed
Figure 2 Kisspeptin stimulates LH secretion in healthy men (ﬁlled squares) and women (ﬁlled circles). The stimulatory effect of kisspeptin on LH secre-
tion is shown in both healthy men and women, when kisspeptin is administered in different isoforms (kisspeptin-54 and kisspeptin-10) and by different
protocols (intravenous or subcutaneous, single boluses or continuous infusion). Note that stimulated LH values are eithermean LHor peak LH concentra-
tions depending on how the data are originally presented.Where authors do not state exact LH concentration following kisspeptin administration, this was
obtained fromthe relevant ﬁgures. 0%change in LHsecretion is reported if no statistically signiﬁcant change in LHsecretionwas reportedandauthors donot
show actual LH concentrations. iv, intravenous; sc, subcutaneous; BD, twice daily; Implanon, etonogestrel contraceptive implant; COCP, combined oral
contraceptive pill.
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that in the early follicular phase, the impact of exogenous kisspeptin is
limited due to high endogenous kisspeptin activity (Chan et al., 2012), al-
though this is speculative. Sex steroid-deﬁcientpost-menopausalwomen
weremore responsive to kisspeptin-10 thanwomen in the early follicular
phase (George et al., 2012) (Fig. 2). Women taking combined estrogen
and progestogen contraceptives showed a minimal response to
kisspeptin-10 (George et al., 2012), contrasting to the larger response
in the physiological luteal phase (Dhillo et al., 2007) (Fig. 2). These
complex relationships suggest that other mechanisms, in addition to
the absolute or relative levels of estrogen and progesterone, appear to
regulate kisspeptin sensitivity across the menstrual cycle and clearly
there remains much to be learnt regarding these inter-relationships.
The expression of kisspeptin receptor in different sex steroid environ-
ments has not been described in primates and data in lower species
remain contradictory (Navarro et al., 2004a, Yamada et al., 2007; Li
et al., 2012). Changes in pituitary sensitivity to GnRH and sex steroid
feedback at that level (Hall et al., 1994; Shaw et al., 2010) add to the com-
plexity of analysis of in vivo studies.
The sexual dimorphism in the responsiveness of men and women has
been elegantly illustrated using the different isoforms of kisspeptin (Jaya-
sena et al., 2011). Men respond to modest doses of both kisspeptin-54
and kisspeptin-10. In a study of healthy women in the early follicular
phase, kisspeptin-10 administered as an intravenous bolus, subcutane-
ous bolus or as an intravenous infusion did not result in a detectable
LH response (Jayasena et al., 2011) (Fig. 2). In another study however,
a low-dose intravenous bolus of kisspeptin-10 induced an LH response
in normal women in the early follicular phase (George et al., 2012).
These differences may have been methodological—as the Jayasena
et al. (2011) protocol did not involve baseline sampling. In the study by
George et al. (2012), a 10-min baseline LH sampling for 180 min was
employed prior to kisspeptin administration, enabling comparison of
LH secretion before and after kisspeptin-10 infusion in the same individ-
ual. Given the small sample number, small effect size and inter-individual
variability in baseline LH, this lack of baseline data to enable
intra-individual comparisons diminishes statistical sensitivity to identify
small changes in LH. A small but signiﬁcant increase in LH in response
to kisspeptin-54 administered intravenously or subcutaneously in the
early follicular phase was also observed (Dhillo et al., 2007; Jayasena
et al., 2011), indicating that the response to the longer isoform is substan-
tially more robust, perhaps reﬂecting its longer half-life. Sexual dimorph-
ism in the kisspeptin system is also seen in rodent models: females have
signiﬁcantly more kisspeptin neurones than males in the AVPV nucleus
(Oakley et al., 2009). This sexual variation in anatomical distribution of
the kisspeptin pathway and the response to kisspeptin administration
may reﬂect sexually dimorphic roles of kisspeptin, notably in the gener-
ation of the pre-ovulatory LH surge, which is unique to the female.
Kisspeptin mediates negative sex steroid
feedback
Patterns of GnRH and subsequently LH secretion across the menstrual
cycle are modulated by gonadal steroid feedback. During the follicular
phase of the menstrual cycle GnRH activity and thus LH secretion is
limited by estradiol (E2)-mediated negative feedback (with additional
action on pituitary gonadotrophs) (Karsch, 1987; Shaw et al., 2010).
Thebasis for the change topositive feedbackwith elaborationof themid-
cycle LH surge has long been unclear. GnRH neurones do not express
ERs, suggesting that a separate population of neurones acts as amediator
to relay theovulation-inducingmessage fromgonads to thehypothalamic
GnRH neurones. Recent evidence suggests that KNDy neurones appear
to constitute this ‘missing link’, mediating both negative and positive sex
steroid feedback.
Kisspeptin in the infundibular nucleus mediates negative feedback of
estrogen in humans (Fig. 1). In post-menopausal women kisspeptin neu-
rones in the infundibular nucleus were hypertrophied and expressed
more KISS1 mRNA than in premenopausal women (Rometo et al.,
2007). These hypertrophied neurones expressed both ESR1 (encoding
ER alpha) and neurokinin B mRNA, had increased expression of neuro-
kinin B and showed a similar distribution to that of kisspeptin neurones
(Rance et al., 1990; Rance and Young, 1991). The suggestion that kis-
speptin and neurokinin B in the infundibular nucleus act synergistically
to mediate estrogen negative feedback is supported by animal data,
showing an up-regulation of Kiss1 mRNA expression in ovariectomised
rodents, sheep andmonkeys in the arcuate nucleus (equivalent to the in-
fundibular nucleus in humans) but not in more rostral areas, and that this
was prevented by E2 replacement (Oakley et al., 2009; Lehman et al.,
2010). Consistent with this, the intracerebroventricular administration
of kisspeptin antagonist prevented the LH rise in castrated rodents
(Roseweiret al., 2009). Similarly, ovariectomy increasedandestrogen re-
placement reduced neurokinin B gene expression in the infundibular
nucleus of monkeys (Abel et al., 1999; Sandoval-Guzman et al., 2004).
Theseﬁndings together imply that estrogenmediates its negative feed-
backbysuppressing kisspeptin andneurokininB release fromKNDyneu-
rones, which reduces their stimulatory input to GnRH neurones (Fig. 1).
The converse, i.e. inhibitory, involvement of the opioid component of
this signalling system has long been recognized. The colocalization of
dynorphin in at least some kisspeptin and neurokinin B-containing neu-
rones in the human is discussed above (section: Kisspeptin neurone
populations co-express other neuropeptides). Naloxone, an opioid re-
ceptor antagonist, increased serum LH levels in late follicular and luteal
phases of the menstrual cycle (Quigley and Yen, 1980; Shoupe et al.,
1985). This effect was not apparent in post-menopausal and oophorec-
tomized young women, whereas replacement of estrogen or progester-
one restored the ability of naloxone to release LH (Melis et al., 1984;
Casper andAlapin-Rubillovitz, 1985; Shoupe et al., 1985). The endogen-
ous opioid peptide dynorphin mediates this role physiologically, and
inhibited GnRH and LH pulse frequency following progesterone admin-
istration (Ferin et al., 1984; Karsch, 1987; Goodman et al., 2004). In con-
trast, the opioid receptor antagonist naltrexone increased serum LH
concentrations and LH pulse amplitude in women with hypothalamic
amenorrhoea (Genazzani et al., 1995). The relative deﬁciency of dynor-
phin signalling as part of negative estrogen feedback in the post-
menopausal and oophorectomized states would appear a likely explan-
ation for the lack of response to naloxone in hypergonadotrophic states,
in contrast to potentially increased dynorphin signalling contributing to
the hypogonadotrophic state in hypothalamic amenorrhoea. It is
however possible that already near maximal LH secretion in sex
steroid deﬁcient post-menopausal and oophorectomized women
would account for the inability of naloxone to further stimulate gonado-
trophin release although kisspeptin-10 induced LH secretion in post-
menopausal women (George et al., 2012). In post-menopausal
women, the expression of prodynorphin mRNA in the infundibular
nucleus is reduced (Rometo and Rance, 2008). The role of dynorphin
as a mediator of sex steroid negative feedback is consistent with data
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from the ewe, where dynorphin is coexpressedwith kisspeptin and neu-
rokinin B, both of which show a high degree of colocalization with ER
alpha andprogesterone receptors in thearcuatenucleus, and theexpres-
sion of prodynorphin mRNA is suppressed by ovariectomy (Goubillon
et al., 2000; Foradori et al., 2002, 2005; Franceschini et al., 2006;
Goodman et al., 2007). This is distinct from the apparent situation in
rodents where, despite colocalization of KNDy neurones with both es-
trogen and progesterone receptors, dynorphin does not seem to
mediate estrogen negative feedback (Navarro et al., 2009).
In summary, it appears that in humans KNDy neuronesmediate nega-
tive sex steroid feedback in the infundibular nucleus by suppressing the
secretion of kisspeptin and neurokinin B and stimulating the secretion
of dynorphin, which act synergistically to reduce the activity of the
GnRH neuronal system, and thus gonadotrophin secretion.
Kisspeptin may also mediate estrogenic
positive feedback
Estrogen feedback switches from negative to positive in the late follicular
phase to induce the GnRH/LH surge at the time of ovulation. However,
the neuroendocrine mechanisms involved in this critical physiological
event have been unclear. Emerging data suggest that although the nega-
tive feedback of sex steroids ismediated by KNDy neurones in the infun-
dibular/arcuate nucleus, the positive feedback of sex steroids is more
site and species speciﬁc (Fig. 1).
Recent data support a potential role for kisspeptin in generating the
ovulatory LH surge in humans. Kisspeptin-54 (subcutaneous in doses
of 1.6–12.8 nmol/kg (9.4–75 mg/kg), used instead of hCG during an
FSH/GnRH antagonist assisted conception ovulation induction proto-
col, induced an LH surge and triggered oocyte maturation, with subse-
quently a live term birth reported (Abbara et al., 2013). Repeated
twice-daily administration of kisspeptin-54 shortened the menstrual
cycle and advanced the onset of the LHpeak in healthywomen (Jayasena
et al., 2013b). This is in keepingwith data fromanimalmodels. Kisspeptin
administration results in an early LH surge in sheep, and conversely ad-
ministration of kisspeptin antiserumor antagonists to rats and sheeppre-
ventedorblunted the LHsurge (Kinoshita et al., 2005;Caratyet al., 2007;
Clarkson et al., 2008; Pineda et al., 2010).
The anatomical site of kisspeptin that relays positive sex steroid feed-
back is different in rodents compared with humans and other species. In
rodents the AVPV nucleus is the location of estrogen positive feedback,
which is not matched in humans, other primates and sheep, where kis-
speptin neurones in the infundibular/arcuate exert this function
(Fig. 1). The expression of Kiss1 mRNA in the AVPV nucleus is dramat-
ically increased after estrogen replacement and at the time of the
GnRH/LH surge (Smith et al., 2005, 2006b). There are no studies
looking at the anatomical region of kisspeptin expression that mediates
estrogen positive feedback in humans and evidence comes from other
species, which, like humans, have no homologous area to the AVPV
nucleus. In sheep, the expression of Kiss1 mRNA in the arcuate
nucleus is markedly enhanced during the pre-ovulatory LH surge
(Smith et al., 2008b). In rodents the AVPV nucleus receives afferent
ﬁbres from the suprachiasmatic nucleus, the location of circadian
clock, which coordinates and provides precise timing for the LH surge
and the kisspeptin system in nowbeing integrated into our understanding
of the neurobiology of this system across species, including the human
(Christian and Moenter, 2010; Khan and Kauffman, 2012).
KNDy neurones may have a role in positive estrogen feedback. In
sheep, the neurokinin B receptor agonist senktide increased LH secre-
tion close to levels seen during the pre-ovulatory LH surge (Billings
et al., 2010). KNDyneurones do notmediate positive estrogen feedback
in rodents basedon their location in thearcuatenucleusonly (Burkeet al.,
2006; Goodman et al., 2007; Navarro et al., 2009). Other neurotrans-
mitters may also contribute to the kisspeptin-mediated LH surge, as
kisspeptin populations in the preoptic area/RP3V and the infundibular/
arcuate nucleus co-localize with different peptides (see above section:
Kisspeptin neurone populations co-express different neuropeptides).
Kisspeptin stimulates gonadotrophin release
in disease models
In addition to being a potent stimulator of LH secretion in healthy men
and women, the ability of kisspeptin to induce LH release in human
disease models characterized by low gonadotrophin secretion has
been investigated (Fig. 3).
Hypothalamic amenorrhoea
Hypothalamic amenorrhoea is characterized by slowGnRH pulsatile se-
cretion, resulting in a preferential decline in LH compared with FSH se-
cretion and low ovarian follicular activity. As, by deﬁnition, this is a
functional rather than pathological condition, it might be readily cor-
rected by administration of kisspeptin to increase GnRH secretion.
Hypothalamic amenorrhoea was the ﬁrst disease model used to
explore the therapeutic potential of kisspeptin-54, which when admini-
strated as subcutaneous bolus at 6.4 nmol/kg (37 mg/kg) resulted in a
10-fold increase in LH and 2.5-fold increase in FSH secretion, both to
normal physiological levels (Jayasena et al., 2009) (Fig. 3). However,
this increase in gonadotrophins did not translate into a signiﬁcant eleva-
tion in E2 secretion, suggesting that folliculogenesis was not restored,
conﬁrmed by ovarian quiescence on ultrasound scan (Jayasena et al.,
2009). The lack of ovarian activity may relate to the limited effect on
FSH secretion and the short timescale of study. Despite the initial stimu-
lation of LH and FSH secretion, when kisspeptin-54 was injected twice
daily for 2 weeks, these increases were not sustained with LH falling to
pretreatment levels, suggesting tachyphylaxis (Jayasena et al., 2009,
2010) (see section: Continuous exposure to kisspeptin can cause desen-
sitization). However, sustained secretion of gonadotrophins at physio-
logical levels was achieved with intermittent subcutaneous injection of
kisspeptin-54 twice weekly (6.4 nmol/kg (37 mg/kg)) for 8 weeks, al-
though it did not result in increased E2 secretion or follicular de-
velopment (Jayasena et al., 2010). It has subsequently been shown
that an infusion of kisspeptin-54 (0.01 nmol/kg/h (0.059 mg/kg/h) to
1 nmol/kg/h (5.9 mg/kg/h)) for 8 h inwomenwith hypothalamic amen-
orrhoea can induce LH pulsatility with a 3-fold increase in LH pulse fre-
quency and mass per pulse (Jayasena et al., 2013a). The ability of the
increased gonadotrophin secretion, and perhaps the relative effects of
LH and FSH, to bring about ovarian activity and menstrual cycles will de-
termine the therapeutic application of kisspeptin in this condition.
In all the studies above, regardless of the dose and routeof administra-
tion, the LH response to kisspeptin is 5-fold greater in hypothalamic
amenorrhoea than in healthy women in the early follicular phase. This
is consistent with data from a rodent model of undernutrition showing
up-regulated hypothalamic Kiss1r mRNA expression (Castellano et al.,
2005). Altered GnRH sensitivity is unlikely as the effect of GnRH on
8 Skorupskaite et al.









LHsecretion is similar in hypothalamic amenorrhoea andhealthywomen
in the early follicular phase (Jayasena et al., 2009; George et al., 2012).
Hypogonadism in men with type 2 diabetes
Men with type 2 diabetes often have low testosterone concentrations,
and inappropriately low LH indicating a hypothalamic/pituitary basis
(George et al., 2010). As with hypothalamic amenorrhoea, increasing
LH secretion by administration of kisspeptin might therefore have thera-
peutic potential. This has been explored in a small number of such men,
investigating the response to both bolus administration and infusion of
kisspeptin-10 (George et al., 2013) (Fig. 3). Kisspeptin-10 intravenous
bolus administration (0.3 mg/kg (0.23 nmol/kg)) increasedLHsecretion
2-fold in diabetic hypogonadal men, i.e. of the same magnitude as in
healthy men with peak mean LH 10.7 IU/l and 14.5 IU/l, respectively
(George et al., 2013). An infusion of kisspeptin-10 for 11 h at a higher
dose (4 mg/kg/h (3.1 nmol/kg/h)) produced a more profound 5-fold
increase in LH release (George et al., 2013), also comparable to the re-
sponse in healthy men (George et al., 2011). Kisspeptin-10 also stimu-
lated LH pulse frequency in diabetic men with hypogonadotropic
hypogonadism, which was sustained for the duration of the infusion
(11 h) with no evidence of a decline in LH (i.e. no desensitization) over
that timescale (George et al., 2013). Importantly, serum testosterone
was also elevated into the normal physiological range (George et al.,
2013). The ability of kisspeptin to robustly increase LH pulsatility with
anassociated increase in testosterone is veryencouraging, but thepoten-
tial of kisspeptin to maintain gonadotrophin and sex steroid release
for longer periods of time relevant to therapeutic use has yet to be
determined.
Neurokinin B signalling deﬁciencies
Patients with loss-of-functionmutation in neurokinin B (TAC3) and its re-
ceptor (TAC3R) show hypogonadotropic hypogonadism characterized
by failure to progress through puberty (Topaloglu et al., 2009). It is pos-
tulated that inability of neurokinin B in an autocrine and/or paracrine
manner to stimulate kisspeptin secretion results in low GnRH pulse fre-
quency with correspondingly low LH and gonadal steroid levels but
normal ornear-normal levels of FSH typically seen in thesepatients.Neu-
rokinin B, being potentially upstream of kisspeptin in neuroendocrine
Figure3 Increase in LHsecretion following the administrationof kisspeptin inhumandiseasemodels.The stimulatoryeffectof kisspeptinonLHsecretion
is shown in reproductive endocrine disorders, when kisspeptin is administered in different isoforms (kisspeptin-54 and kisspeptin-10) and by different pro-
tocols (i.v. or s.c., single boluses or continuous infusion) as indicated. Note that stimulated LH values are either mean LH or peak LH concentrations de-
pendingonhowthedataareoriginally presented.Whereauthorsdonot state anexactLHconcentration followingkisspeptin administration, this is obtained
from the relevant ﬁgures. BD, twice daily; T2DM, type 2 diabetes; NKB (TAC3), neurokinin B; NKB3R (TAC3R), neurokinin B receptor.
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signalling, makes kisspeptin an attractive therapeutic agent to restore
GnRH secretion in patients with defects in the neurokinin B system.
Indeed, continuous infusion of kisspeptin-10 (1.5 mg/kg/h (1.1 nmol/
kg/h) for 12 h) in two patients with TAC3 and two patients with TAC3R
mutation stimulated the LH response 2.5-fold (Young et al., 2013)
(Fig. 3). Overall, the LH response to kisspeptin was more limited than
that achieved in healthy men using the same protocol (George et al.,
2011) with lower LHmass per pulse, although pulse frequency was nor-
malized, consistent with complex neuropeptide interactions associated
with KNDy neurone function rather than a linear hierarchy, as described
above. Nevertheless, a signiﬁcant increase in testosterone levels in male
patients and in E2 levels in the single female patient was achieved (Young
et al., 2013).
Continuous exposure to kisspeptin can cause
desensitization
Continuing administration of GnRH desensitizes the HPG axis after an
initial stimulation, by down-regulation of GnRH receptors and desensi-
tization of gonadotrophes (Belchetz et al., 1978; McArdle et al., 1987;
Mason et al., 1994). There is evidence for pulsatile (i.e. non-continuous)
secretion of kisspeptin within the hypothalamic median eminence of the
monkey (Keen et al., 2008). Continuous administration of kisspeptin-10
(intravenous 200 mg/h (154 nmol/kg) or 400 mg/h (307 nmol/kg) for
98 h) to rhesus monkeys resulted in suppressed LH secretion, indicative
of kisspeptin receptor desensitization (Ramaswamyet al., 2007). Thekis-
speptin receptor has also been shown to desensitize in vitro (Pampillo
et al., 2009).Consistentwith this, repeated subcutaneous administration
of kisspeptin-54 (6.4 nmol/kg (37 mg/kg) twice daily) for 2 weeks in
womenwith hypothalamic amenorrhoea resulted in an initial stimulation
of LH and FSH which was not maintained (Jayasena et al., 2009) (Fig. 3).
Howeverother studies in humansusing infusionsor repeatedadministra-
tion of kisspeptin have not provided consistent evidence for desensitiza-
tion (Figs 2 and 3). More recently, infusion of a lower dose of
kisspeptin-54 for 8 h (from 0.01 nmol/kg/h (0.059 mg/kg/h) to
1 nmol/kg/h (5.9 mg/kg/h)) in women with hypothalamic amenor-
rhoea not only caused sustained LH secretion but also restored LH pul-
satility (Jayasena et al., 2013a) (Fig. 3). Continuous exposure to
kisspeptin-54 administered twice daily for 1 week advanced the men-
strual cycle in healthy women (Jayasena et al., 2013b). Similarly, continu-
ous kisspeptin-10 infusion at 4 mg/kg/h (3.1 nmol/kg/h) for 22.5 h in
healthymen showed continuing stimulation of LH secretion, with no evi-
dence of desensitization (George et al., 2011) (Fig. 2). In contrast, LH se-
cretion was not sustained in three healthy men during infusion of
kisspeptin 10 for 24 h at 12 mg/kg/h (9.2 nmol/kg/h), the highest
dose used in humans to date (Lippincott et al., 2013). However, LH se-
cretion remainedwell above baseline at the endof infusion, in contrast to
themarked desensitization observedwith a high dose of kisspeptin-54 in
womenwith hypothalamic amenorrhoea (Jayasena et al., 2009) (Fig. 2). It
wouldbe interesting todetermine if LHsecretion remains abovebaseline
or if LH decreases to castrate levels with kisspeptin infusion for longer
than 24 h. These data therefore suggest that while high doses of both
kisspeptin-54 and kisspeptin-10 may induce desensitization, this does
not occur at lower doses. In a dose-ﬁnding study involving bolus injection
of kisspeptin-10, the highest dose (3 mg/kg (2.3 nmol/kg)) resulted in a
sub-maximal LH response, consistent with desensitization even with
bolus administration of kisspeptin-10 (George et al., 2011) (Fig. 2).
An alternative explanation for this observation is that at that high dose
kisspeptinmight have stimulated another RF-amine receptor, such as go-
nadotrophin inhibitory hormone receptor, known to have an inhibitory
effect on GnRH and LH (George et al., 2011).
Consistent with these ﬁndings, intermittent administration of kisspep-
tin results in sustained GnRH and LH pulsatility. Intermittent administra-
tion of kisspeptin-10 in juvenile male monkeys (intravenous hourly for 2
days) and juvenile female rats (intracerebroventricular twice daily for 5
days) caused precocious puberty (Navarro et al., 2004b, Plant et al.,
2006). Kisspeptin-54 (6.4 nmol/kg (37 mg/kg/h)) injected twice
weekly sustained the secretion of gonadotrophins for an 8-week
period after a brief initial suppression (Jayasena et al., 2010) (Fig. 3).
The ability of natural forms of kisspeptin to induce desensitization in
humans thus remains unclear, with the discrepancies between studies
possibly reﬂecting the duration of kisspeptin injection (8–22.5 h versus
2 weeks), lower doses of kisspeptin infused in the human studies com-
pared with primate studies, variation in the isoforms of kisspeptin
used, the mode of kisspeptin administration, differences between the
human and animal models and sex and even health status (healthy men
versus women with hypothalamic amenorrhoea). Kisspeptin receptor
agonist analogues have also been developed, and two of these,
TAK-448 and TAK-683, are potent inducers of desensitization with po-
tential use to suppress gonadotrophin secretion and thus gonadal func-
tion, similar to the GnRH analogues widely used today. Phase I clinical
studies in healthy men show that subcutaneous infusion of TAK-448
(0.01–1 mg/day) and TAK-683 (0.01–2 mg/day) for 2 weeks rapidly
suppress testosterone below castration levels (MacLean et al., 2013;
Scott et al., 2013).
Kisspeptin and puberty
The demonstration of the obligate role of kisspeptin-GPR54 signalling in
human puberty was the ﬁnding that ﬁrmly established kisspeptin as a
crucial regulator of reproductive function. In 2003, two independent
groups identiﬁed ‘inactivating’ point mutations and deletions in KISS1R
thatwereassociatedwith impairedpubertal development insomepatients
with hypogonadotropic hypogonadism (de Roux et al., 2003; Seminara
et al., 2003). Mutations in KISS1Rwere demonstrated in both consanguin-
eous families and in unrelated patients. In addition, Kiss1r- and Kiss1-
deﬁcient mice displayed a virtually identical phenotype (Funes et al.,
2003; Seminara et al., 2003; d’Anglemont de Tassigny et al., 2007).
Conversely an ‘activating’ mutation (Arg386Pro) in the kisspeptin re-
ceptor gene was identiﬁed in a girl with precocious puberty, although in-
heritance could not be determined as the biological family was not
available for genetic testing (Teles et al., 2008). Cells transfected with
themutant kisspeptin receptor showedprolongedaccumulationof inosi-
tol phosphate and phosphorylation of extracellular signal-regulated
kinase, indicatingextended intracellular signalling (Teles et al., 2008).Mis-
sense mutations have also been described in the KISS1 gene in three un-
related children with central precocious puberty (Silveira et al., 2010).
Thismutant kisspeptin ismore resistant to in vitrodegradation, suggesting
greater bioavailability as the cause of precocious puberty (Silveira et al.,
2010).
Hypothalamic expression of Kiss1 and Kiss1r mRNA is dramatically
up-regulated at puberty in rodents and primates (Navarro et al.,
2004a, Han et al., 2005; Shahab et al., 2005) and the percentage of
GnRH neurones depolarizing in response to kisspeptin increases from
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juvenile (25%) to prepubertal (50%) to adult mice (.90%), suggesting
that GnRH neurones acquire sensitivity to kisspeptin across puberty
(Han et al., 2005). Kisspeptin-54 secretion and speciﬁcally kisspeptin-54
pulse frequency increase at the onset of puberty in monkeys (Keen et al.,
2008). In addition to these physiological changes linking kisspeptin signal-
ling to the timing of puberty, the administration of exogenous kisspeptin
resulted in earlier puberty in rats and monkeys (Navarro et al., 2004b,
Plant et al., 2006). Conversely, administration of a kisspeptin antagonist
inhibited pulsatile GnRH release in pubertal monkeys and delayed
puberty in rats (Roseweir et al., 2009; Pineda et al., 2010). The ﬁndings
strongly support a requirement for KISS1/GPR54 signalling to initiate
and progress through puberty in a range of species.
Kisspeptin andmetabolism
Human reproductive function is inﬂuenced by both extremes of
nutrition—undernutrition and obesity. Kisspeptin may provide a link
between nutritional/metabolic status and reproduction by sensing
energy stores and translating this information into the pulsatile secretion
ofGnRH.TheexpressionofKiss1mRNAandgonadotrophin secretion is
reduced inmice, pubertal rats andmonkeys subject to fasting (Castellano
et al., 2005; Cota et al., 2006; Roa et al., 2009;Wahab et al., 2011). Kis-
speptin is able to restore delayed vaginal opening and increases low go-
nadotrophin and estrogen levels associated with chronic undernutrition
in pre-pubertal rats (Navarro et al., 2004b, Castellano et al., 2005).
Humans with mutations in leptin or leptin receptor show hypogonad-
ism (Farooqi and O’Rahilly, 2009). The leptin receptor (Ob-Rb) is not
present on GnRH neurones, but 40% of kisspeptin neurones in the
mouse arcuate nucleus express the leptin receptor (Smith et al., 2006a),
suggesting a role for kisspeptin in mediating the metabolic signals of
leptin on the HPG axis. Leptin-deﬁcient mice show decreased expression
of Kiss1 mRNA, which is partially up-regulated by leptin (Smith et al.,
2006a). Incomplete restoration of Kiss1 mRNA expression suggests that
other mediators are involved in inhibiting kisspeptin signalling in leptin de-
ﬁciency. Furthermore,micewith selective deletionof leptin receptor from
kisspeptin neurones display normal pubertal development, sexual matur-
ation and fertility, demonstrating that leptin action on kisspeptin neurones
is not obligatory for these processes (Donato et al., 2011).
Low levels of testosterone have also been observed in men with
obesity and type 2 diabetes, where decreased secretion of GnRH is
thought to be the causative factor (Dandona et al., 2008). A rat model
of diabetes (streptozocin treated) has reduced levels of hypothalamic
Kiss1mRNAwith subsequently low levels of circulating gonadotrophins
and sex steroids, which are corrected by kisspeptin (Castellano et al.,
2006, 2009). This raises the possibility that diminished kisspeptin secre-
tion is a potential mechanism for hypogonadotropic hypogonadism in
patients with obesity and diabetes (George et al., 2010). Indeed, as
described above, kisspeptin-10 increased LH pulse frequency and LH
secretion in hypogonadal men with type 2 diabetes (George et al.,
2013). The likely pathways for down-regulation of kisspeptin signalling
include negative feedback by estrogen, which is markedly elevated in
obesity (Schneider et al., 1979), resistance to leptin, also seen in
human obesity (Finn et al., 1998), insulin resistance and hyperglycaemia
(Castellano et al., 2006, 2009), and inﬂammation, which is up-regulated
in hypogonadal men with diabetes (Dandona et al., 2008) and is asso-
ciated with decreased kisspeptin expression in rats (Iwasa et al., 2008).
Current data indicate that kisspeptin acts downstream to metabolic
signals and conveys information about energy stores toGnRHneurones,
thereby regulating reproduction. This gives promise for a potential novel
therapeutic roleofkisspeptin to restore the reproductive axis in conditions
of negative energy balance, such as anorexia nervosa, and in diabetes.
Clinical applications of KNDy
manipulation
GnRHanalogues are extensively used in clinical practice in the treatment
of hormone-dependent diseases and infertility. Current therapies ma-
nipulate the HPG axis at the level of GnRH receptors on pituitary gona-
dotrophs, largely to suppress gonadal function, e.g. in the treatment of
prostate and breast cancer, endometriosis and uterine ﬁbroids. As re-
productive endocrine conditions can be broadly categorized into those
with pathologically diminished (delayed puberty, hypothalamic amenor-
rhoea, hypogonadism in diabetes) andpathologically enhanced (polycys-
tic ovary syndrome (PCOS), menopause, precocious puberty) GnRH
andassociated gonadotrophinpulsatility, thenewly discoveredhypothal-
amic peptides kisspeptin and neurokinin B offer a novel therapeutic ap-
proach with potential advantages over the existing therapies in several
clinical contexts (Fig. 4).
Figure 4 Potential clinical applications of novel kisspeptin-based
modulation of LH secretion. Schematic presentation of LH pulses in
health and in reproductive endocrine disorders. In health, an LH pulse
occurs about every 90 min. The frequency of LH pulses is diminished
in patients with hypothalamic amenorrhoea, male hypogonadism and
pubertal delay, whereas LH pulse frequency is enhanced in women
with polycystic ovary syndrome, menopause and precocious puberty.
Therapeutic opportunities to correct abnormal LH pulse frequency by
manipulating KNDy neurones with relevant agonists and antagonists
are emerging. PCOS, polycystic ovary syndrome.
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Manipulation of KNDy neurones to stimulate
HPG axis
Enhancing the stimulatory tone of kisspeptin and neurokinin B by appro-
priate agonists and suppressing the inhibitory tone of dynorphin by its
antagonists, may have therapeutic potential for diseases with decreased
gonadotrophin secretion. Exogenous kisspeptin enhances diminished
LHpulsatility in hypogonadalmenwith diabetes and stimulates LH secre-
tion in women with hypothalamic amenorrhoea (Jayasena et al., 2010;
George et al., 2013). Kisspeptin initiates puberty in monkeys and
rodents, but this has not been tested in children with delayed puberty
(Navarro et al., 2004b, Plant et al., 2006). Pulsatile gonadotrophin secre-
tion is restoredby kisspeptin administered to patientswith hypogonado-
tropic hypogonadism secondary to mutations in neurokinin B and/or its
receptor (Young et al., 2013). The role of dynorphin antagonists, such as
naloxone, in patients with abnormally low LH secretion remains to be
elucidated.
Kisspeptin therapy has the potential to ‘ﬁne tune’ IVF techniques. Kis-
speptin triggered the LH surge during following ovulation induction for
assisted reproduction (Abbara et al., 2013) with successful achievement
of a live birth. Kisspeptin might stimulate a more physiological pattern of
gonadotrophin secretion, avoiding the risk of ovarian hyperstimulation
syndrome associated with currently used hCG injections although
clearly much remains to be discovered regarding potential advantages
and disadvantages over current approaches.
Manipulation of KNDy neurones to inhibit
HPG axis
Suppressing the stimulatory role of kisspeptin and neurokinin B by specif-
ic receptor antagonists and enhancing the inhibitory action of dynorphin
by its receptor agonist is desirable in scenarios of increasedGnRH pulsa-
tility where a reduction rather than complete suppression of GnRH is
required. Increased frequencyofGnRHand thereforeLHpulsatile secre-
tion (with little effect on FSH secretion) is central to the pathophysiology
of PCOS, themost common endocrinopathy in women. AsGnRHpulse
frequency primarily determines LH but not FSH secretion (McNeilly
et al., 2003), slowing GnRHmight normalize the relative LH hypersecre-
tionoften seen in PCOS.Normalizationof LHsecretion (andperhaps the
consequent hyperandrogenism) in PCOS may promote folliculogenesis
and ovulation. Studies using a neurokinin B antagonist are currently
underway to reduce high LH secretion in PCOS.
The ability of kisspeptin antagonists to limit follicular development and
inhibit ovulation offers potential for a novel female contraceptive,
perhaps being speciﬁcally advantageous in the scenarios where exogen-
ous estrogen is contraindicated. However it might be limited by the
resulting lackof progesterone exposure and adverse effects on the endo-
metrium. Given the preferential stimulation of LH secretion in response
to kisspeptin in humans (Dhillo et al., 2005, 2007; George et al., 2011,
2012), kisspeptin antagonists might potentially result in relative sparing
of FSH comparedwith LH, whichmight reduce or prevent the unwanted
side effects of estrogendeﬁciency, such as vasomotor symptoms and risk
of osteoporosis, associated with GnRH analogue administration.
A similar therapeutic approachmight support theuseof kisspeptin and
neurokinin B suppressive therapies in the treatment of precocious
puberty. Similarly, it may alleviate menopausal hot ﬂushes since KNDy
neurones project to preoptic thermoregulatory areas that express neu-
rokininB receptor in rats andKNDyneuroneablation reducescutaneous
vasodilation (Burke et al., 2006; Rance, 2009; Hrabovszky et al., 2010;
Krajewski et al., 2010; Mittelman-Smith et al., 2012; Rance et al.,
2013).Although the inhibitory roleof opioids onGnRHandLHpulsatility
is well known, manipulation of this system does not have the apparent
speciﬁcity of the kisspeptin or neurokinin B pathways.
The potential more subtle effects of kisspeptin antagonists reducing
LH pulsatility contrast with the profound suppression resulting from
GnRH analogue administration, decreasing gonadotrophin and sex
steroid secretion tocastration levelswith consequent sideeffects, includ-
ing hot ﬂushes, loss of libido and decreased bone mineral density (Rose-
weir et al., 2009). Complete suppression of gonadotrophins and sex
steroids is necessary is some conditions, such as prostate cancer, but
partial suppression is more appropriate in benign prostatic hyperplasia,
endometriosis and uterine ﬁbroids. Clinical effectiveness in the manage-
ment of endometriosis and uterine ﬁbroids withGnRH suppressionwith
add back, and with selective progesterone receptor modulators
(Chabbert-Buffet et al., 2005), suggests that approaches not based on
complete suppression of theHPG axis have clear clinical value. Targeted
partial gonadotrophin suppression, such as that afforded via kisspeptin
and/or neurokinin B inhibition, has the potential to overcome the exist-
ing drawbacks of GnRH analogues although the emerging data on kis-
speptin analogues (MacLean et al., 2013; Scott et al., 2013)
demonstrate the potential for profound suppression as well.
Conclusions
The discovery of kisspeptin has transformed our understanding of the
neuroendocrine signals controlling the reproductive axis. Kisspeptin
coordinates GnRH secretion, mediates gonadal steroid negative and
positive feedback, controls the onset of puberty, and relays information
regarding the body’s energy stores. The last decade has thus seen a huge
resurgence in interest in neuroendocrinology, and thepotential for trans-
lational application is already being explored in human studies. However,
much remains to be learnt before kisspeptin can replace or be used in
conjunctionwithGnRHand gonadotrophin analogues, the currentmain-
stay of infertility and reproductive endocrine disorder treatments.
The mode of kisspeptin administration, as with most peptides,
remains a challenge and there is thus the need for novel approaches
and the development of non-peptide analogues, which is already well
underway. These will also allow reﬁnement of experimental approaches
to explorephysiological pathways (such as elaborationof the importance
of the sex steroid environment) as well as novel treatment strategies
across awide rangeof conditions requiringmanipulation of gonadal func-
tion. Co-administration of kisspeptin, opioid and neurokinin Bmodifying
agents will allow ﬁne modulation of the HPG axis that may open new
therapeutic avenues.
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